Dry Age-Related Macular Degeneration

LumiThera has completed the second tranche of its Series C funding round to support clinical testing and commercialization of the Valeda light delivery system in dry age-related macular degeneration, according to a press release.

Zimura, a complement factor C5 inhibitor, reduced geographic atrophy growth in a phase 2b clinical trial, according to a press release from Iveric bio.

SAN FRANCISCO — More patients with dry age-related macular degeneration treated with risuteganib, a small synthetic peptide that regulates select integrin functions involved in the pathogenesis of the disease, experienced an eight or more letter gain in best corrected visual acuity 12 weeks after treatment compared with a sham group, according to a speaker here.

Here are some of the past week’s top stories on Healio.com/OSN: